Synaptic loss is the cardinal feature linking neuropathology to cognitive decline in Alzheimer's disease (AD). However, the mechanism of synaptic damage remains incompletely understood. Here, using FRET-based glutamate sensor imaging, we show that amyloid-β peptide (Aβ) engages α7 nicotinic acetylcholine receptors to induce release of astrocytic glutamate, which in turn activates extrasynaptic NMDA receptors (eNMDARs) on neurons. In hippocampal autapses, this eNMDAR activity is followed by reduction in evoked and miniature excitatory postsynaptic currents (mEPSCs). Decreased mEPSC frequency may reflect early synaptic injury because of concurrent eNMDAR-mediated NO production, tau phosphorylation, and caspase-3 activation, each of which is implicated in spine loss. In hippocampal slices, oligomeric Aβ induces eNMDARmediated synaptic depression. In AD-transgenic mice compared with wild type, whole-cell recordings revealed excessive tonic eNM-DAR activity accompanied by eNMDAR-sensitive loss of mEPSCs. Importantly, the improved NMDAR antagonist NitroMemantine, which selectively inhibits extrasynaptic over physiological synaptic NMDAR activity, protects synapses from Aβ-induced damage both in vitro and in vivo.
Synaptic loss is the cardinal feature linking neuropathology to cognitive decline in Alzheimer's disease (AD). However, the mechanism of synaptic damage remains incompletely understood. Here, using FRET-based glutamate sensor imaging, we show that amyloid-β peptide (Aβ) engages α7 nicotinic acetylcholine receptors to induce release of astrocytic glutamate, which in turn activates extrasynaptic NMDA receptors (eNMDARs) on neurons. In hippocampal autapses, this eNMDAR activity is followed by reduction in evoked and miniature excitatory postsynaptic currents (mEPSCs). Decreased mEPSC frequency may reflect early synaptic injury because of concurrent eNMDAR-mediated NO production, tau phosphorylation, and caspase-3 activation, each of which is implicated in spine loss. In hippocampal slices, oligomeric Aβ induces eNMDARmediated synaptic depression. In AD-transgenic mice compared with wild type, whole-cell recordings revealed excessive tonic eNM-DAR activity accompanied by eNMDAR-sensitive loss of mEPSCs. Importantly, the improved NMDAR antagonist NitroMemantine, which selectively inhibits extrasynaptic over physiological synaptic NMDAR activity, protects synapses from Aβ-induced damage both in vitro and in vivo.
α7-nicotinics | astrocytes | glutamate receptors E merging evidence suggests that the injurious effects of amyloid β peptide (Aβ) in Alzheimer's disease (AD) may be mediated, at least in part, by excessive activation of extrasynaptic or perisynaptic NMDARs (eNMDARs) containing predominantly NR2B subunits (1, 2) . In contrast, in several neurodegenerative paradigms, physiological synaptic NMDAR (sNMDAR) activity can be neuroprotective (refs. 3-8, but see ref. 9) . Soluble oligomers of Aβ are thought to underlie dementia, mimic extracellular glutamate stimulation of eNMDARs, and disrupt synaptic plasticity and long-term potentiation, eventually leading to synaptic loss (1, 6, 10, 11) . However, mechanistic insight into the action of Aβ that causes excessive eNMDAR stimulation and the potential link between eNMDARs and synaptic damage remain to be elucidated. Here, we examine the cascade involved in eNMDAR activation by oligomeric Aβ and its consequences on miniature excitatory postsynaptic currents (mEPSCs). We found that eNMDAR activation is triggered by extrasynaptic glutamate released from astrocytes in response to Aβ peptide. In turn, eNMDAR stimulation is followed rapidly by a decrease in mEPSC frequency with accompanying generation of nitric oxide (NO), hyperphosphorylation of tau, and activation of caspase-3. Pharmacological blockade of eNMDARs with relative sparing of sNMDARs abrogated NO production, tau phosphorylation, caspase activation, and subsequent synaptic loss. These results suggest a glutamate-mediated cascade triggered by Aβ in which early eNMDAR activation may contribute to subsequent synaptic damage and consequent cognitive decline in AD.
Results

FRET-Based Imaging of Aβ-Induced Glutamate Release from Cultured
Astrocytes. Inflammatory cells, including microglia and astrocytes, are thought to contribute to damage in AD, in part via glutamate excitotoxicity (2, 12) . For example, exposure to oligomeric Aβ or conditioned medium from microglial cultures incubated with Aβ has been reported to decrease glutamate reuptake from astrocytes in brain slices and cultures (13) (14) (15) (16) , but whether Aβ also induces local release of toxic glutamate levels onto neurons remains unknown. To study this question, we used a FRET-based
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Communication between nerve cells occurs at specialized cellular structures known as synapses. Loss of synaptic function is associated with cognitive decline in Alzheimer's disease (AD). However, the mechanism of synaptic damage remains incompletely understood. Here we describe a pathway for synaptic damage whereby amyloid-β 1-42 peptide (Aβ ) releases, via stimulation of α7 nicotinic receptors, excessive amounts of glutamate from astrocytes, in turn activating extrasynaptic NMDA-type glutamate receptors (eNMDARs) to mediate synaptic damage. The Food and Drug Administration-approved drug memantine offers some beneficial effect, but the improved eNMDAR antagonist NitroMemantine completely ameliorates Aβ-induced synaptic loss, providing hope for disease-modifying intervention in AD.
glutamate sensor system (SuperGluSnFR) (17) to detect the local concentration of glutamate contiguous to astrocytes after exposure to Aβ peptides. To ensure the close apposition of the sensor probe (consisting of GluSnFR-transfected HEK 293 cells) to the astrocytes, the sensor cells were genetically engineered to coexpress neuroligin (18) (Fig. 1A) . Unlike prior methods, the FRET GluSnFR technique allows unprecedented spatial and temporal resolution of local glutamate concentration on a subsecond timescale. This resolution was important for comparing extrasynaptic glutamate levels with the rapid electrophysiological effects of Aβ observed in subsequent patch-clamp recordings.
In mixed neuronal/astrocytic or astrocyte cultures, the addition of glutamate itself resulted in an increased normalized FRET ratio, with a standard curve revealing sensitivity in the dynamic range of 1 to ∼100 μM, as reported previously (17) , and similar to the glutamate sensitivity of native NMDARs (19) . Within seconds of exposure to picomolar concentrations of naturally occurring Aβ prepared from human postmortem AD brain by a method modified from Selkoe and colleagues (1, 15, 20) or to nanomolar concentrations of oligomerized (but not monomeric) synthetic Aβ 1-42 , we observed local increases in glutamate. Potentially, both neurons and glia contribute to glutamate release in our mixed cultures, so we also tested the response to Aβ in pure astrocyte cultures. In this case, the change in glutamate concentration was on the order of 30 μM and occurred in ∼40% of the fields of astrocytes examined ( Fig. 1 B-D Fig. S1 .) Although naturally occurring Aβ yielded robust responses, synthetic Aβ 1-42 yielded significant increases in local glutamate with as little as 325 pM of an oligomerized preparation in both rat and human astrocyte cultures (Fig. S1D) . HPLC analysis validated these results, revealing a small but significant rise in glutamate in the medium bathing the astrocytes after Aβ exposure (Fig. S1E) . Depleting microglia from the astrocyte cultures using L-leucine methyl ester did not influence the level of glutamate (Fig. S1F) , arguing for a direct effect of Aβ 1-42 on astrocytes under our conditions. Additionally, low-micromolar Aβ 25-35 also engendered local increases in glutamate release from astrocytes, as detected by the FRET GluSnFR technique (Fig. S1G) . Control experiments showed that the transfected HEK cells did not respond to Aβ in the absence of astrocytes. ] i ) in astrocytes (24) , and glutamate release was calcium dependent, we next asked if α-bungarotoxin (α-Bgtx), a highly selective α7-antagonist, could inhibit Aβ-induced glutamate release from astrocytes. When oligomerized Aβ was applied to mouse astrocytes in the presence of 100 nM α-Bgtx, glutamate release was almost totally abrogated (Fig. 1F) . Moreover, astrocytes obtained from α7nAChR-knockout mice released very little glutamate in response to Aβ, as monitored with the FRET GluSnFR probe (Fig. 1G) . The decrease in Aβ-induced glutamate release was mirrored by a reduction in [Ca 2+ ] i in α7nAChR-knockout astrocytes as compared with WT (Fig. 1H) . These findings support the notion that in addition to the reported inhibition of glutamate reuptake, Aβ induces release of glutamate from astrocytes, mediated at least in part by α7nAChRs. Aβ has been shown to bind to group I metabotropic glutamate receptors (25) , but antagonists to these receptors manifested little or no effect on oligomeric Aβ-induced glutamate release in our system (Fig. S1H) .
A caveat to these findings lies in the fact that astrocytic receptors and their pharmacological properties can change in culture. Hence, to vet our results showing extracellular glutamate accumulation in response to Aβ and its pharmacological properties in more intact systems, we performed experiments in vivo in animal models of AD during microdialysis. Using transgenic mice expressing human amyloid precursor protein (hAPP tg), we found basal glutamate levels were increased compared with nontransgenic littermates and that this increase was largely abrogated and was not statistically different from WT after crossing with α7nAChR-null mice (Fig. 1I and Fig. S1I) . Our results show that extracellular glutamate accumulates not only in culture but also in living brain in the presence of oligomerized Aβ in an α7nAChR-dependent manner (23) . As a corollary, under our culture conditions as well as in vivo, the high density of transporters adjacent to synaptic sites would be expected to clear excessive glutamate released by Aβ away from synaptic receptors, although extrasynaptic receptors still might be activated (but see ref. 26 ). Hence, this premise was queried next.
Aβ Increases Extrasynaptic Glutamatergic Currents but Decreases
Synaptic Currents in Rat Hippocampal Autaptic Cultures. Hippocampal microcultures contain a few or even a single neuron that synapses on itself to form an autapse; neurons are cultured in isolation or on a tiny bed of astrocytes ( Fig. S2 A and B) . This preparation allows rapid access of exogenous Aβ and applied drugs to neural tissue and also simultaneous recording of eNMDARs and sNMDARs with a single patch electrode. In hippocampal autaptic cultures, we found that picomolar naturally occurring Aβ-soluble oligomers, nanomolar oligomeric Aβ 1-42 (but not monomeric), or low-micromolar Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (but not Aβ ) induced a tonic inward current within tens of seconds of application in ∼55% of neurons (Fig. 2 A-G; n = 90). In excitatory neurons in the nominal absence of extracellular Mg 2+ , the inward current was inhibited by the NMDAR antagonists (D-)-2-amino-5-phosphonovalerate (APV) or memantine ( Fig. 2F ) or by the combination of an NMDAR antagonist and an AMPA receptor (AMPAR) antagonist ( Fig. 2 A-C). Prior work had shown that the tonic inward current in this preparation represents activation of extrasynaptic glutamate receptors (3, 5, 27, 28) . To confirm this finding, we performed recordings after pharmacological isolation of extrasynaptic currents using the published protocol of first activating excitatory synaptic currents electrically followed by the addition of dizocilpine (MK-801) to block these synaptic responses (29) (Fig. S2 C and D) . After isolating extrasynaptic currents in this manner, we found that Aβ 1-42 (containing 250-nM oligomers) resulted in increased eNMDAR activity similar to that seen with the application of low-micromolar glutamate (Fig. S2E ).
When we studied autapses formed by inhibitory neurons, which release GABA rather than glutamate (Fig. S2F) , we also observed a tonic inward current engendered by oligomerized Aβ that was antagonized at least partially by 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX) plus memantine (Fig. 2D ). This finding is consistent with the notion that glutamate was being released predominantly by astrocytes rather than neurons, because these inhibitory neurons do not release glutamate. If so, then the addition of α-Bgtx to these neuronal/astrocyte cultures should inhibit oligomerized Aβ 1-42 -induced currents by inhibiting glutamate release from the astrocytes via blocking α7nAChRs. To test this premise in a manner that was pathophysiologically relevant to human AD, we used neurons and astrocytes derived from human induced pluripotent stem cells (hiPSCs). Consistent with the notion that astrocytic glutamate release is mediated by α7nAChRs, we found in this preparation that NMDAR antagonists inhibited oligomerized Aβ 1-42 -induced currents, as did 100 nM α-Bgtx ( Another important consideration is that memantine, like other NMDAR open-channel blockers, might block α7nAChR channels (30) and hence prevent release of glutamate from the astrocytes. We tested this possibility using our FRET probe and indeed found memantine produced a small decrement in glutamate release from astrocytes, but the effect did not reach statistical significance (Fig.  S1J) . Hence, this action could not account for the memantine effect, because substantial glutamate release remained. Nonetheless, this secondary effect of memantine on α7nAChRs potentially might contribute to the drug's ability to limit eNMDAR currents, because, at least in theory, glutamate release from astrocytes might be inhibited to a degree, in addition to memantine's direct blocking of eNMDAR-operated channels.
Importantly, in neurons in which synaptic currents in addition to extrasynaptic responses were monitored quantitatively after the addition of TTX, we found a decrement in mEPSC frequency and a smaller or no decline in mEPSC amplitude within minutes of Aβ exposure ( Fig. 2 E and H-M). The significant decrease in mEPSC frequency suggested a presynaptic deficit, but functional loss of synapses in response to oligomeric Aβ under these conditions was possible also. We knew these autaptic cells were well clamped, because the miniature synaptic currents reversed at or near 0 mV, as expected for excitatory cation-mediated responses under our conditions. Interestingly, in neurons that did not manifest any extrasynaptic glutamatergic current in response to Aβ, we did not observe a subsequent decrease in mEPSC frequency. Furthermore, depletion of astrocytes from the cultures largely abrogated these effects of oligomeric Aβ (Fig. S2I ), even though excitatory neurons have been shown to release synaptic glutamate in response to Aβ (31) . The fact that the Aβ-induced current was greatly abated in , also induced inward extrasynaptic current sensitive to memantine with a mean amplitude of 45.9 ± 11.2 pA in 42% of recorded cells. (H) In well spaceclamped autapses, both mEPSC amplitude and mEPSC frequency were decreased significantly after exposure to oligomerized Aβ . n = 9; *P < 0.05, **P < 0.01 by t test. (I) Representative cumulative probability graphs of mEPSC amplitudes. (J) Representative cumulative probability graphs of mEPSC interevent intervals. (K) Amplitude of mEPSC was not altered but frequency was decreased significantly after Aβ 25-25 exposure. n = 5; *P < 0.05 by t test. (L) Representative cumulative probability graphs of mEPSC amplitudes. (M) Representative cumulative probability graphs of mEPSC interevent intervals.
the absence of astrocytes also was consistent with the notion that the predominant effect on extrasynaptic current observed here did not result from direct action of Aβ on neuronal NMDARs. Although these experiments do not rule out a direct effect of Aβ on neurons, they do indicate that the major effects observed under our conditions were dependent on the presence of astrocytes.
Additionally, in the absence of TTX we observed that cells responding to Aβ with an inward extrasynaptic current manifested subsequent evoked EPSCs with smaller AMPAR-and NMDAR-mediated components than in control (Fig. S2J) . This result might reflect the development of silent synapses, endocytosis of AMPARs, or sNMDAR depletion resulting from EphB2 binding of exogenous Aβ, as previously reported (10, 32, 33) . However, coupled with the very significant decrease in mEPSC frequency that we observed in the hippocampal autaptic preparation, our results also are consistent with the notion of rapid compromise or functional loss of the synapse after Aβ exposure. Hence, we further investigated this possibility next. ) that was largely abrogated by 5-10 μM memantine and its more potent adamantane nitrate derivative, NitroMemantine ( Fig. 3 A and B and Fig. S3 A-C) (34) . At this concentration in this preparation, we previously have shown that memantine and NitroMemantine preferentially block eNMDARs while relatively sparing sNMDARs (3, 28) . As a control, this effect of Aβ also was largely blocked in cultures depleted of astrocytes. Taken together with the foregoing results, these findings are consistent with the notion that Aβ induced release of glutamate from astrocytes, which in turn activated neuronal eNMDARs.
Excessive influx of Ca 2+ via NMDARs activates neuronal nitric oxide synthase, which generates toxic levels of NO (35, 36) . NO has been shown to contribute to synaptic spine loss after Aβ exposure, at least in part via mitochondrial actions of S-nitrosylated dynamin-related protein 1 (Drp1) after transnitrosylation from cyclin-dependent kinase 5 (Cdk5) enzyme (37, 38) . Accordingly, in our cultures, in addition to a rise in neuronal Ca 2+ levels, Aβ induced an increase in NO, as monitored with diaminofluorescein (DAF) fluorescence imaging (38, 39) . Both memantine and NitroMemantine prevented this Aβ-induced increase in NO (Fig. 3C and Fig. S3B ). Notably, NitroMemantine was significantly more effective than memantine in abrogating the increase in Ca 2+ and toxic NO response, consistent with its more effective tonic blockade of eNMDARs, as previously suggested electrophysiologically (34) . Confirming the involvement of eNMDARs in this process, we also found similar changes in Ca 2+ and NO in response to oligomeric Aβ after pharmacological isolation of extrasynaptic currents using the published protocol of activating excitatory synaptic currents (by antagonizing inhibitory currents with the GABA antagonist bicuculline) followed by the addition of MK-801 to block the excitatory synaptic responses (Fig. S3 D and E) (3, 27, 28) .
Extrasynaptic NMDARs Mediate Aβ-Induced Synaptic Depression in Hippocampal Slices. Previously, Selkoe and colleagues demonstrated that soluble oligomeric Aβ depressed long-term potentiation induced by high-frequency stimulation while enhancing long-term depression induced by electrical (low-frequency) stimulation (1, 15, 20, 40) . Considering that accumulation of extracellular glutamate induced by high levels of oligomeric Aβ, as observed here, might underlie changes in synaptic function and plasticity, we next investigated the effect of Aβ on synaptic depression. To do so, we studied synaptic transmission at the Schaffer collateral-CA1 pathway of the hippocampus using electrophysiological recording of synaptic field potentials in acute hippocampal slices. We observed that as little as 50 nM oligomeric (but not 1 μM monomeric) Aβ 1-42 induced a gradual depression of field excitatory postsynaptic potentials (fEPSPs), outlasting the application of Aβ ( Fig. 4A; n = 12 ). Although the input-output relationship also was affected by oligomeric Aβ 1-42 , paired-pulse facilitation remained largely unaffected (Fig. 4 B and C) .
In some ways, this effect of Aβ was reminiscent of chemical longterm depression, whereby glutamate induces synaptic depression that is modulated, at least in part, by eNMDARs (41-43). Therefore, we asked whether Aβ-induced synaptic depression might be mediated through eNMDARs by applying memantine, which we have shown at low-micromolar concentrations blocks eNMDARs to a relatively greater degree than sNMDARs (3, 28) . We found that 10 μM memantine blocked induction of synaptic depression by 50 nM Aβ 1-42 ( Fig. 4D; n = 4) . Moreover, 500 nM Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (but not Aβ ) induced synaptic depression that was inhibited by 10 μM memantine or 5 μM NitroMemantine (Fig. S4 A and B) . This latter finding is consistent with the greater potency of NitroMemantine at eNMDARs over memantine (Fig. 3 B and C and Fig. S3) .
Next, we hypothesized that if eNMDARs indeed contributed to Aβ-induced synaptic depression, then activation of extrasynaptic receptors by exogenous NMDA (5-50 μM) should recapitulate the synaptic depression caused by Aβ and should be inhibited by low-micromolar memantine or NitroMemantine; in fact, we found this to be the case (Fig. S4C) .
Increased Tonic eNMDAR-Mediated Activity in AD Brain Slices. Given the evidence for activation of eNMDARs after acute application of Aβ, one might expect persistent eNMDAR-mediated activity from long-term accumulation of oligomerized Aβ in the AD brain. Hence, we asked if eNMDARs were tonically overstimulated in transgenic AD models of Aβ overexpression (33) . Indeed, compared with WT littermate controls, we found a significant increase in basal inward current in neurons from the CA1 region of hippocampal slices prepared from hAPP-J20 tg mice in Values for the change in fluorescence intensity were calculated as change in intensity divided by baseline intensity (ΔF/F 0 ) and were plotted as a fraction of 1. Values are mean + SEM for all panels. *P < 0.05, **P < 0.01, ***P < 0.001; n ≥ 40 neurons for each condition. a.u., arbitrary units.
nominal absence of extracellular Mg 2+ ( Fig. 5 ; n = 15, P < 0.01). Pharmacological inhibition by the AMPAR antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) plus the NMDAR antagonist 3-[(R)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPP) showed that this basal current was induced by glutamate ( Fig. 5 A,  B , and E and Fig. S4D ). Moreover, application of 100 nM α-Bgtx largely abrogated the basal current, consistent with the notion that α7nAChRs were mediating release of glutamate in the slices, as encountered earlier in our culture and in vivo AD models. Additionally, CNQX plus CPP blocked mEPSCs in these slices, indicating the glutamatergic nature of these synaptic currents (Fig. 5 A-D) .
Although the small basal glutamatergic currents in some control WT slices (e.g., Fig. 5A ) could be ascribed to leakage or damage, other control slices manifested virtually no basal current (Fig. 5F ). Moreover, memantine (10 μM), which is known to inhibit eNMDARs preferentially over sNMDARs (3, 28) , substantially blocked the basal current in hAPP-J20 slices (Fig. 5 G and H) but had little or no effect on mEPSC amplitude or frequency in WT slices even with incubation periods of more than 1 h (Fig. 5I) . In contrast, after ∼30 min of perfusion with memantine, mEPSCs frequency increased but amplitude and kinetics remained relatively unaffected in hAPP-J20 slices (Fig. 5J) . These findings are consistent with the notion that the loss of synaptic function observed with chronic exposure to Aβ might be partially reversible on a relatively short time scale if excessive eNMDAR activity were inhibited, in this case by memantine.
To obtain evidence independent of memantine that the basal current was indeed mediated by eNMDAR activation, we took advantage of the recent report that glycine is the predominant coagonist of eNMDARs. Thus, by degrading glycine in slice preparations, the enzyme glycine oxidase (GO) can inhibit eNMDAR-mediated responses. In contrast, enzymes that degrade D-serine, such as D-amino acid oxidase (DAAO) or Dserine deaminase (DsdA), can inhibit sNMDAR-mediated responses (44, 45) . We used this approach to provide further proof that the basal inward current seen in the hAPP-J20 slices (and associated with our measurement of extracellular glutamate in these mice by HPLC) is caused by eNMDAR activity, because GO but not DAAO largely blocked this current (Fig.  S5 A and B) .
Next, we studied mEPSCs in hippocampal slices from hAPP-J20 and WT littermates in more detail. We observed a significant decrease in frequency (P < 0.01), a small but insignificant decrease in amplitude, and no change in kinetics of mEPSCs in hAPP-J20 slices compared with WT ( Fig. 5 K-O; n = 12 ).
Extrasynaptic NMDARs Mediate Aβ-Induced Molecular Cascades
Leading to Synaptic Spine Loss. We sought a heuristic explanation for the decrease in mEPSC frequency that occurred in response to Aβ-induced eNMDAR activity in hippocampal autapses and in hAPP-J20 hippocampal slices, as well as for the partial recovery of mEPSC frequency in hAPP-J20 tg slices treated with memantine. One possibility is that the decrease in mEPSC frequency reflects initial synaptic dysfunction that subsequently leads to synapse loss. We reasoned that, if the initial decrease in mEPSC frequency induced by eNMDAR activity truly represented the initial phase of synaptic damage, then the molecular pathway(s) underlying this damage should be engaged early on and that pharmacological blockade of eNMDARs should inhibit these molecular pathways and give protection from subsequent morphological loss of dendritic spines. Such spine loss has been observed to occur ∼16 h after exposure to oligomerized Aβ (1), although an initial decrease in spine volume has been reported as early as 10 min (10). Here, we found that treatment of our mixed neuronal/glial cultures with the standard pharmacological protocol to activate eNMDARs selectively after blocking sNMDARs (using bicuculline exposure followed by MK-801, washout, and then exposure to low concentrations of NMDA) (3, 27, 28) triggered an increase in tau and hyperphosphorylated tau and in caspase-3 activation (Fig. 6 A and C) . When the cultures were exposed to oligomerized Aβ rather than low-dose NMDA, phosphotau increased more dramatically than tau (Fig. 6B) . Importantly, these same pathways involving phospho-tau and caspase-3 previously were shown to be involved in oligomeric Aβ-induced abnormal excitability and synaptic spine loss (10, 11, 14, (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) . For example, the relatively specific inhibitor of caspase-3 activity, z-DEVD-fmk, blocks a pathway leading to dendritic spine shrinkage via activation of calcineurin, which results in dephosphorylation and internalization of synaptic AMPARs (56) . As would be expected for a mechanism involving eNMDAR activation, this effect of Aβ was inhibited by memantine and to an even greater degree by NitroMemantine (Fig. 6B) . In contrast to eNMDARs, selective pharmacological activation of sNMDARs led to a decrease in tau phosphorylation and caspase-3 activation (Fig. 6 A and C) .
To assess the contribution of eNMDAR activity to Aβ-induced synapse loss, we next exposed hippocampal slices to oligomerized Aβ and then treated them with memantine or its improved derivative NitroMemantine to block eNMDARs selectively while relatively sparing sNMDARs (3, 28) . In fact, at equimolar concentrations NitroMemantine (34) is more effective than memantine not only in blocking eNMDAR activity but also in sparing synaptic activity (Fig. 3 B and C, Fig. S3, and Fig. S4 A, B , and E). We found that treatment with these eNMDAR-selective antagonists ameliorated the effect of Aβ on synaptic loss, with NitroMemantine manifesting a larger and more significant protective effect than memantine, as monitored morphologically in YFPlabeled dendritic spines (Fig. 6 D and E) . To confirm that this protective effect was mediated by eNMDARs, we used a second approach to inhibit eNMDARs vs. sNMDARs by bathing hippocampal slices in glycine and D-serine-degrading enzymes (44, 45, 57) . We found that only inhibition of eNMDARs with glycine oxidase significantly protected from spine loss induced by oligomerized Aβ (Fig. S5C) . Taken together, these results suggest that early events associated with hyperactivation of eNMDARs by Aβ indeed may be linked to the subsequent loss of synapses in AD.
Effect of Inhibiting eNMDARs in Vivo in an AD Transgenic Mouse
Model. To test further the effect of inhibiting eNMDARs relative to sNMDARs with memantine and NitroMemantine, we treated the triple transgenic (3× tg) AD mouse model for 3 mo starting at 6 mo of age. This mouse model of AD manifests early synaptic In WT slices, 10 μM memantine manifested little or no effect on the frequency or amplitude of mEPSCs, even with very prolonged incubation times on the order of hours. (J) In slices from hAPP-J20 tg littermates, perfusion with 10 μM memantine for periods ≥30 min resulted in increased frequency of mEPSCs, as reflected by a leftward shift in the interevent interval in the cumulative probability curve, but had only minor or no effect on amplitude. n = 7 slices for I and J. (Insets) Histograms of frequency and amplitude. Data are shown as mean + SEM; *P < 0.01. (K) mEPSCs recorded from CA1 neurons in WT mice in the presence of 1 μM TTX and 50 μM picrotoxin (Vh = −70 mV). (L) mEPSCs recorded in hAPP-J20 tg mice under similar conditions. (M) Cumulative probability showing decreased mEPSC frequency in J20 transgenic vs. WT mice, as reflected by an increase in the interevent interval. n = 12; P < 0.00001 for mEPSC frequency by Kolmogorov-Smirnov test. The noise level was greater in J20 than in WT mice because of the presence of increased basal current from extrasynaptic glutamate. To avoid bias due to this noise level, the analysis of mEPSC frequency used the same event threshold for both sets of data. (N and O) Cumulative probability of mEPSC amplitude and kinetics in hAPP-J20 tg vs. WT mice. n = 12. dysfunction and cognitive deficits in the presence of soluble Aβ and abnormal tau protein before the formation of frank amyloid plaques and tau tangles (58) . We used this mouse because we wanted to analyze the effect of soluble oligomeric Aβ, rather than plaques and tangles, and, unlike other AD mouse models, there were few if any plaques or tangles when the mice were treated. Moreover, this mouse model displayed only very mild loss of neurons in the neocortex and hippocampus, despite a dramatic loss of synapses. Hence, neuronal loss could not account for the decrease in synapses. By quantitative confocal immunofluorescence microscopy in both the cortex and hippocampus, after treatment we observed a significant increase in synaptic and dendritic density by synaptophysin and microtubuleassociated protein 2 (MAP2) staining, respectively (Fig. 7 A-E) . As in the hippocampal slice preparation, NitroMemantine demonstrated an effect superior to that of memantine. Additionally, in behavioral studies of hippocampal function, NitroMemantinetreated (but not memantine-treated) 3× tg AD mice displayed significantly improved function on the location-novelty recognition test (Fig. 7F) .
Discussion
Recent studies suggest that eNMDAR activity inhibits neuroprotective pathways and signals neuronal injury, whereas sNMDAR activity stimulates neuroprotective transcriptional and antioxidant pathways (6) . Although this paradigm first was demonstrated for ischemic brain disease, accumulating evidence suggests that it also is true for neurodegenerative disorders involving protein misfolding, such as Huntington disease (3, 4) and AD (7, 8, 59, 60) . Additionally, linking this dichotomy of eNMDAR vs. sNMDAR activation to synaptic integrity, we and others previously have shown that low levels of glutamate or endogenous synaptic activity may enhance dendritic spine growth (61, 62) . Moreover, normal endogenous levels of Aβ may increase mEPSC frequency, reflecting increased physiological synaptic glutamate release (31) . In contrast, excessive glutamate, leading to eNM-DAR activation, can precipitate loss of dendrites and spines (6, 61 ). Here we demonstrate that soluble oligomeric Aβ engages astrocytic α7nAChRs to induce glutamate release from astrocytes, with local levels in the extracellular space approaching tens of micromolar. In turn, resulting neuronal eNMDAR activation leads to both functional and molecular changes, heralding synaptic showing that synaptic activity reduced and extrasynaptic NMDAR activity increased the levels of tau and phospho-tau (p-tau) in mixed neuronal/glial cultures. Quantification is shown relative to the level of actin as the loading control. *P < 0.05, **P < 0.01, and ***P < 0.001 by ANOVA. (B) Blockade of extrasynaptic relative to synaptic NMDAR activity using memantine or NitroMemantine (5 μM each) decreased p-tau and to a lesser degree total tau levels after exposure to oligomerized Aβ . n = 3. The effect of NitroMemantine was greater than that of memantine. Quantification is shown relative to actin. *P < 0.01, **P < 0.001, ***P < 0.05 by ANOVA. (C) Western blots showing that synaptic activity reduced and extrasynaptic NMDAR activity increased cleaved caspase-3. Quantification is shown relative to actin. *P < 0.01, **P < 0.001 by ANOVA. (D and E) Blockade of eNMDAR activity by NitroMemantine abrogated dendritic spine loss mediated by oligomerized Aβ in hippocampal slices to a greater degree than memantine. Hippocampal neurons from YFP-transgenic mice were exposed for 7 d to control or synthetic Aβ 1-42 (500-nM oligomers) in the presence or absence of memantine or NitroMemantine (each at 10 μM). n > 12 for each condition; *P < 0.001, **P < 0.05. Histograms for all panels show mean + SEM.
damage. Strikingly, these changes occur within minutes of Aβ-induced eNMDAR activation, before actual histological loss of the synapse, which can take several hours to observe (1). Our finding that α7nAChRs play a significant role in Aβ-induced glutamate release from astrocytes is in agreement with prior studies showing that α7nAChRs represent a binding site for Aβ (22) . Moreover, the present study links the cholinergic and glutamatergic systems in AD and as such may lead to additional strategies for therapeutic intervention. Importantly, our findings also indicate that Aβ-induced neuronal synaptic loss in AD may, in large part, be dependent on non-cell-autonomous actions of oligomeric Aβ on glial cells (in our case astrocytes), although the involvement of microglia also has been implicated in other studies.
Intriguingly, we found that Aβ induced a tonic glutamatergic current in hippocampal neurons. This extrasynaptic inward current, at least in part mediated by astrocytic glutamate release and subsequent activation of eNMDARs, was followed by a decrement in mEPSC frequency. We reasoned that the decrease in mEPSC frequency that we observed with Aβ exposure in both hippocampal autapses and slices might represent initial synaptic dysfunction, which only later was followed by frank synapse loss. Additionally, eNMDAR-mediated increases in NO generation, tau protein, tau hyperphosphorylation, and caspase-3 activity that we found in response to oligomerized Aβ argue that these early molecular events presage the loss of synapses that we observed hours later. Prior experiments had shown that after acute exposure to Aβ (10, 32, 63) , other synaptic events also may occur, such as internalization via endocytosis of postsynaptic receptors to account for a decrease in mEPSC amplitude. However, this mechanism alone would not adequately account for the decrease in mEPSC frequency (but not amplitude) that we observed after chronic Aβ exposure in the hAPP-J20 hippocampus and that was reversed, at least partially, with prolonged memantine treatment. Importantly, the concentration of memantine we used correlates well with the dosage approved by the Food and Drug Administration for treatment of moderate-to-severe AD in humans (3, 28) , and these results may account, at least in part, for the drug's beneficial albeit modest effect.
Although under our conditions memantine and NitroMemantine inhibit sNMDARs relatively less than eNMDARs (3, 28) , it might be argued that the drugs' protective effect on synapses actually was mediated via their more minor sNMDAR effects rather than by their major action on eNMDARs. However, we believe that this possibility is highly unlikely, given that Aβ exposure decreased mEPSCs, reflecting in part less sNMDAR activity, whereas the presence of memantine and NitroMemantine preserved and actually increased this activity. Hence, it would appear that, under the conditions in which memantine and NitroMemantine protected synapses from Aβ-induced damage, the relatively minor inhibition of sNMDARs by these drugs could not have been responsible. Therefore, we conclude that inhibition of excessive eNMDAR activity likely was responsible for the beneficial effect on synaptic protection. The corollary of this conclusion is that Aβ-induced eNMDAR activity was in large part responsible for synaptic dysfunction/loss, because we found that inhibition of this aberrant activity protected the structure and function of the synapses.
Concerning the mechanism of Aβ-induced eNMDAR activity on synaptic damage, the pharmacological data presented here and elsewhere (37, 38) indicate that tau phosphorylation, caspase-3 activation, and NO-mediated events [formation of S-nitrosylated (SNO)-Drp1 and SNO-Cdk5] all appear to be largely mediated by eNMDARs. Because these events occur rapidly, within minutes of eNMDAR activation, the early changes that we observed in synaptic function could serve as the harbinger of subsequent synaptic damage and loss. Critically, our empirical data indicate that these untoward effects on synaptic form and function are reversible, at least in part, after eNMDAR inhibition (e.g., by memantine and even more effectively by NitroMemantine) in both hippocampal slices and in vivo rodent models of AD.
Previously, Aβ was thought to injure the synapse directly, and changes in glutamate receptors and synapses were considered readouts of this damage. Here, we present evidence that glutamate itself, after Aβ-induced release from astrocytes, is responsible, at least in part, for triggering synaptic loss. Additionally, the effect of eNMDAR vs. sNMDAR activity on Aβ production and oligomerization (7, 8, 59, 60) could produce a positive feedback loop whereby oligomerized Aβ induces eNMDAR activity, as shown here, and eNMDAR activity also triggers toxic Aβ generation (Fig. 7G) . These findings have considerable influence on our view of potential disease-modifying drugs for AD, implying that synapse protection may be achieved by eNMDAR antagonists that are sufficiently potent to protect but also are gentle enough to allow normal synaptic transmission and neurobehavioral improvement, as we observed here with the newer NitroMemantine drug both in vitro and in vivo. and dendritic marker MAP2 in 3× tg AD mice treated with vehicle, memantine, or NitroMemantine. n = 9; *P < 0.05, **P < 0.01. (F) Improvement in neurobehavioral assessment of hippocampal function on the location novelty recognition test [or novel location (NL)] in 9-mo-old 3× tg AD mice after a 3-mo treatment with NitroMemantine compared with the effect of memantine or vehicle-treated control. In this task, the number of contacts with the object in the final familiarization trial before the object was moved (Old Location) and the number of contacts made after the same object was moved (New Location) were monitored. There were no group differences in initial contacts with the three objects, and all were explored between five and seven times during the first familiarization trial. Only the NitroMemantine-treated group manifested a significant increase in their ability to detect spatial change, as monitored by the increased number of contacts with the object after it was moved. *P < 0.03 by ANOVA; n = 24. (G) Schematic diagram showing influence of eNMDAR activity on Aβ-induced synaptic damage in AD.
Materials and Methods
Cell Cultures. Mixed neuronal/glial rat cerebrocortical cultures and purified rat, mouse, and human astrocytes were prepared following standard protocols with some modifications (37) . For studying autapses, microisland rat hippocampal cultures were prepared as previously described (SI Materials and Methods) (28).
Generation of hiPSC-Derived Neurons from Dermal Fibroblasts. To generate hiPSCs from human dermal fibroblasts, we used an integration-free reprogramming method that used electroporation of three episomal expression vectors collectively encoding six reprogramming factors, namely OCT3/4, SRYbox containing gene 2 (SOX2), Kruppel-like factor 4 (KLF4), L-MYC, LYN28, and p53-shRNA) (64) . hiPSC colonies were maintained on mouse embryonic fibroblast feeders and were validated for pluripotency, trilineage differentiation capability, and karyotypic stability as previously described (65) (SI Materials and Methods).
Glutamate FRET Imaging. Using FRET microscopy of the SuperGluSnFR probe (17), we monitored glutamate release from mixed neuronal/glial and pure astrocyte cultures (SI Materials and Methods).
Glycine and D-Serine Degradative Enzymes. Recombinant glycine oxidase (GO) and D-serine deaminase were purified as described (57) . D-Amino acid oxidase) was purchased from a commercial source (Calzyme). All enzymes were kept frozen and were dissolved immediately before use.
Aβ Preparations. Human synthetic Aβ 1-42 (GenicBio or Anaspec) was dissolved following established procedures. Naturally occurring soluble Aβ dimers and trimers were prepared by size-exclusion chromatography from postmortem human AD cortex, with minor modifications of the procedure described previously (1, 15, 20, 40) . By ELISA, this preparation contained 220 pM of Aβ before 1:4 dilution for use in experiments at a final concentration of 55 pM. For all Aβ preparations, concentration and quality were assessed by ELISA and Western blot analysis (SI Materials and Methods).
Measuring Aβ Oligomer Concentration by Dynamic Light Scattering. The Aβ oligomeric concentration was analyzed as reported previously (SI Materials and Methods) (66).
Electrophysiology. For hippocampal autaptic cultures, whole-cell recordings were performed on single neurons located on microislands of one or more astrocytes. Recordings were performed on 14-26 d in vitro cultures at room temperature using a patch-clamp amplifier (Axopatch 200B or MultiClamp 700A; Molecular Devices). Drugs were administered via a fast valve-controlled perfusion system (Lee Company). All antagonists were purchased from Tocris Bioscience unless otherwise noted. The NitroMemantine derivative used in these studies is the lead drug candidate designated YQW-036/NMI-6979 (34) . For data acquisition and analysis, signals were filtered, digitized, and stored in a computer (Dell) using PClamp v.10 software (Axon Instruments). Display and analysis of data distributions were carried out using a statistical software package (Origin 7, OriginLab Corp.) (SI Materials and Methods).
[ ] i concentrations in cells in primary cultures were measured using DAF FM diacetate (2.5 μM) and Fura-2/AM (4 μM), respectively (SI Materials and Methods).
Pharmacological Isolation of eNMDARs from sNMDARs. To assess the effect of eNMDARs selectively, we initially activated sNMDARs by a brief (7-10 min) application of bicuculline (50 μM) to block inhibitory transmission and then blocked the sNMDARs with the long-lasting NMDAR inhibitor MK-801 (10 μM), as previously described (3, 5, 28) . After bicuculline and MK-801 were washed out from the dish, NMDA or Aβ (to release glutamate from astrocytes) was added to elicit eNMDAR-dependent signaling.
Dendritic Spine Analysis. Thy1-YFPH transgenic mice (8-10 d old) were used to prepare organotypic hippocampal slices using the interface method. Dendritic spine density was evaluated as described previously (37, 40) (SI Materials and Methods).
Quantitative Confocal Immunohistochemistry. To determine the in situ integrity of the presynaptic and dendritic complex of the hippocampus and neocortex, 40-μm-thick vibratome sections were cut from paraformaldehydefixed brain and were immunolabeled with mouse monoclonal antibodies against synaptophysin (SY38; 1:500; Millipore) and MAP2 (1:100; Millipore) (SI Materials and Methods).
Western Blot Analysis of Tau, Phospho-Tau, and Caspase-3. sNMDARs and eNMDARs (by exposure to 100 μM NMDA) or oligomerized Aβ (by exposure to 250 μM NMDA) were stimulated for 15 min to 1 h; then cell lysates were prepared as described previously (3) . Western blots were probed for phospho-tau (AT8; Thermo), tau (TAU-5; Millipore), cleaved caspase-3 (Cell Signaling), and actin (Millipore) (SI Materials and Methods).
Neurobehavioral Analysis. The novel object exploration tests included the location novelty recognition test and the object novelty recognition tests to assess spatial learning as well as object learning (SI Materials and Methods).
HPLC Analysis of Glutamate Concentration. After 30 min incubation in oligomerized Aβ , culture medium was boiled and cleared by centrifugation (10,000 × g for 10 min) to remove insoluble materials. Subsequently, samples were diluted in 20 mM borate buffer at pH 9.0 and were derivatized for 1 min with N-tert-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde. Samples then were separated in a 5-mm C18 reverse-phase column (220 × 4.6 mm) Sheri-5 (Brownlee), and glutamate was monitored by fluorescence (334 nm excitation and 433 nm emission) using an L-7485 detector (Hitachi).
Memantine and NitroMemantine Treatment. Mice were treated with memantine or NitroMemantine as previously described (SI Materials and Methods) (3).
In Vivo Microdialysis. All procedures were conducted in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines. Microdialysis procedures were performed as previously described (67) on 12-mo-old and 20-to 24-mo-old male and female mice of the following genotypes: hAPP tg, α7KO, and hAPP tg/α7KO (23) . Dialysate samples were analyzed as previously reported (68) (SI Materials and Methods).
Statistical Analysis. A Student t test was used for two-way comparisons, and an ANOVA with Tukey's HSD test was used for multiple comparisons. For cumulative probability curves, comparisons were made using the Kolmogorov-Smirnov test. Results are expressed as mean ± SEM.
